Quarterly report · Q2

Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥115.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥58.4bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥230.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥112.6bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥55.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥34.6bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥16.6bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥36.3bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥17.6bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥37.3bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥17.5bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥74.3bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥38.1bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥18.3bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥23.4bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥11.0bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥49.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥24.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥11.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥25.1bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥11.6bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥26.0bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥12.5bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥461.0bnat 2023-09-30Cons.Assets IFRS
Total assets¥400.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥377.7bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥115.8bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥91.1bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥345.2bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥291.3bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥331.6bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥302.6bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥284.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥135.1bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥100.2bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥26.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥57.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥25.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥28.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.9bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥18.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥15.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥14.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥34.472023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥16.192023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥72.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥35.442022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥17.582022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥34.452023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥16.182023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥72.172022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥35.422022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥17.572022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio71.9%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.3%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-09-30−¥754m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-09-30−¥754m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥125m
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-09-30−¥42m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2023-07-01 → 2023-09-30¥3.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2023-07-01 → 2023-09-30¥3.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥21m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥6m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.3bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2023-07-01 → 2023-09-30¥674m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2023-07-01 → 2023-09-30¥6.9bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2023-07-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥215m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥101m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2023-07-01 → 2023-09-30¥1.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-09-30¥45.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2023-07-01 → 2023-09-30¥23.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-09-30¥44.0bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2023-07-01 → 2023-09-30¥22.9bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥622m
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-09-30¥18.4bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2023-07-01 → 2023-09-30¥9.5bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-09-30¥32.7bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2023-07-01 → 2023-09-30¥16.9bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-09-30¥32.6bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2023-07-01 → 2023-09-30¥16.9bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥11m
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥0
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-09-30¥7.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2023-07-01 → 2023-09-30¥3.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2023-07-01 → 2023-09-30¥7.7bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2023-07-01 → 2023-09-30¥7.7bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥4m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.8bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2023-07-01 → 2023-09-30¥945m
—segment totalrevenue2023-04-01 → 2023-09-30¥116.4bn
—segment totalrevenue2023-07-01 → 2023-09-30¥58.5bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥114.6bn
—segment totalrevenue external2023-07-01 → 2023-09-30¥57.8bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.7bn
—segment totalrevenue intersegment2023-07-01 → 2023-09-30¥733m
—segment totalsegment profit2023-04-01 → 2023-09-30¥34.4bn
—segment totalsegment profit2023-07-01 → 2023-09-30¥16.5bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2.8bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥2.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥701m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥231m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥8.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥2.9bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥445m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥179m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.5bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥634m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥14.0bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥6.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.7bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥6.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥347m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥185m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-09-30¥42.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2022-07-01 → 2022-09-30¥22.3bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-09-30¥40.9bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2022-07-01 → 2022-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥664m
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2022-07-01 → 2022-09-30¥10.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-09-30¥30.2bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2022-07-01 → 2022-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-09-30¥30.2bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2022-07-01 → 2022-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥4m
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥2m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2022-07-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥8.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥18.5bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥8.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥304m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥865m
—segment totalrevenue2022-04-01 → 2022-09-30¥113.9bn
—segment totalrevenue2022-07-01 → 2022-09-30¥55.9bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥111.2bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥54.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥2.7bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥1.0bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥36.9bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥17.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 811
ItemContextValueUnit
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember679012800
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember679014300
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant679012800
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant679014300
Number of shares heldCurrentQuarterInstant_No1MajorShareholdersMember230458000
Shareholding ratioCurrentQuarterInstant_No1MajorShareholdersMember0.339
Number of shares heldCurrentQuarterInstant_No2MajorShareholdersMember97855000
Shareholding ratioCurrentQuarterInstant_No2MajorShareholdersMember0.144
Number of shares heldCurrentQuarterInstant_No3MajorShareholdersMember53952000
Shareholding ratioCurrentQuarterInstant_No3MajorShareholdersMember0.079
Number of shares heldCurrentQuarterInstant_No4MajorShareholdersMember28102000
Shareholding ratioCurrentQuarterInstant_No4MajorShareholdersMember0.041
Number of shares heldCurrentQuarterInstant_No5MajorShareholdersMember20200000
Shareholding ratioCurrentQuarterInstant_No5MajorShareholdersMember0.030
Number of shares heldCurrentQuarterInstant_No6MajorShareholdersMember19474000
Shareholding ratioCurrentQuarterInstant_No6MajorShareholdersMember0.029
Number of shares heldCurrentQuarterInstant_No7MajorShareholdersMember8891000
Shareholding ratioCurrentQuarterInstant_No7MajorShareholdersMember0.013
Number of shares heldCurrentQuarterInstant_No8MajorShareholdersMember8231000
Shareholding ratioCurrentQuarterInstant_No8MajorShareholdersMember0.012
Number of shares heldCurrentQuarterInstant_No9MajorShareholdersMember8094000
Shareholding ratioCurrentQuarterInstant_No9MajorShareholdersMember0.012
Number of shares heldCurrentQuarterInstant_No10MajorShareholdersMember6009000
Shareholding ratioCurrentQuarterInstant_No10MajorShareholdersMember0.009
Number of shares heldCurrentQuarterInstant481266000
Shareholding ratioCurrentQuarterInstant0.709
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember45100
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember678819600
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember6788196
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember148100
Number of shares issued shares voting rightsCurrentQuarterInstant679012800
Number of voting rights issued shares voting rightsCurrentQuarterInstant6788196
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member45100
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member45100
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0001
Number of shares held in own name treasury shares etcCurrentQuarterInstant45100
Number of shares held in others names treasury shares etcCurrentQuarterInstant-
Total number of shares held treasury shares etcCurrentQuarterInstant45100
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0001
Cash and cash equivalents IFRSPrior1YearInstant118319000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant135053000000JPY
Trade and other receivables ca IFRSPrior1YearInstant50537000000JPY
Trade and other receivables ca IFRSCurrentQuarterInstant52493000000JPY
Other financial assets ca IFRSPrior1YearInstant28069000000JPY
Other financial assets ca IFRSCurrentQuarterInstant33137000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass